The inhibition of arginase, resulting in higher arginine (ARG) availability for nitric oxide synthesis, may account for the putative protective effect of homoarginine (HOMOARG) against atherosclerosis and cardiovascular disease. However, uncertainty exists regarding the significance of HOMOARG-induced arginase inhibition in vivo. A novel UPLC-MS method, measuring the conversion of ARG to ornithine (ORN), was developed to determine arginase 1 and arginase 2 inhibition by HOMOARG, lysine (LYS), proline (PRO), agmatine (AG), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and NG-Monomethyl-L-arginine (L-NMMA). Plasma HOMOARG, ARG and ORN concentrations were further measured in 50 healthy older adults >65 years (27 males and 23 females). HOMOARG inhibited arginase 1 with IC 50 and K i values of 8.14 ± 0.52 mM and 6.1 ± 0.50 mM, and arginase 2 with IC 50 and K i values of 2.52 ± 0.01 mM and 1.73 ± 0.10 mM, respectively. Both arginase isoforms retained 90% activity vs. control when physiological HOMOARG concentrations (1-10 µM) were used. In partial correlation analysis, plasma HOMOARG was not associated with ARG (P = 0.38) or ARG/ ORN ratio (P = 0.73) in older adults. Our results suggest that arginase inhibition is unlikely to play a significant role in the reported cardio-protective effects of HOMOARG.
HOMOARG was found to be an inhibitor, but not a substrate, of arginase 2 17 . More recently, Michel has reproposed HOMOARG as a potential arginase substrate 19 .
In view of the conflicting results of previous studies, clarification of the role of HOMOARG in modulating the activity of the arginase isoforms 1 and 2 will have significant biological and clinical relevance. We sought to address this issue by studying the effects of HOMOARG, in addition to other endogenous molecules such as lysine (LYS), proline (PRO), agmatine (AG), asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and NG-Monomethyl-L-arginine (L-NMMA), on arginase 1 and 2 activity. LYS was selected as a positive control for arginase inhibition, as it is the prototypic arginase inhibitor [10] [11] [12] [13] [14] [15] . In contrast, ADMA, SDMA, L-NMMA, important modulators of the NO pathway together with ARG and HOMOARG, have failed to show inhibitory potential when incubated with arginase, and were selected as negative controls 18, 19 . Additionally, PRO and AG, previously described as poor arginase inhibitors 10, 11, [14] [15] [16] [17] 21 , were included in this study. The concentration range used for the compounds tested was chosen in order to cover their physiological concentrations found in plasma and up to 10,000-fold their circulating concentrations.
Our in vitro experimentation utilised a highly sensitive and specific UPLC-MS method to measure arginase activity, from an expression system that better represents physiological conditions. Specifically, we incubated our samples in phosphate buffer, abundant in living organism, instead of the commonly reported tris-buffer, and we used un-purified cell lysate as the source of protein. Lysates were obtained from cells overexpressing arginase 1 or arginase 2 in the absence of EDTA to maintain the cellular concentrations of divalent ions, removing the need for manganese supplementation. We also investigated the inhibitory potential of HOMOARG on arginase activity in vivo by assessing the associations between HOMOARG concentrations and the ARG/ORN ratio in a cohort of healthy older adults.
Results
Cloning and expression of arginase 1 and arginase 2. HEK293T cells stably expressing recombinant human arginase 1 or arginase 2 were analysed using immunological detection. Both arginase enzymes were observed at an apparent molecular weight of 40 kDa ( Fig. 1 and Supplementary File) as expected according to the antibodies manufacturer. Immunoreactive bands were not observed when probing arginase 1 lysates with anti-arginase 2 antibody, and vice versa.
UPLC-MS analysis of ORN.
Extracted ion chromatograms (EICs) were obtained with a mass window of 0.02 Da from total ion chromatogram (TIC) using m/z of 133.11 and 139.15 corresponding to the parent ions ([M + H] + ) of ORN and ORN-d6 respectively (Fig. 2) . Calibration curves were obtained by plotting the peak area ratio ORN to internal standard versus the standard concentration.
ORN quantification was linear between 0 and 200 µM ( Fig. 3) , with a limit of detection of 3 and 0.1 µM for arginase 1 and arginase 2 assays, respectively, and a limit of quantitation of 10 and 0.3 µM for arginase 1 and arginase 2, respectively. The limit of detection was calculated as the ORN concentration corresponding to 3:1 signal to noise ratio, whereas the limit of quantitation was calculated as the ORN concentration corresponding to 10:1 signal to noise ratio.
Characterisation of arginase 1 and arginase 2 kinetic parameters.
Linear conditions for the conversion of ARG into ORN were observed up to 20-min time for arginase 1 and up to 40-min time for arginase 2 (Fig. 3 ). ORN conversion was not linear across the range of protein concentrations investigated, with the same trend observed for both arginase 1 and arginase 2 ( Fig. 3 ). Reproducibility of ORN formation was assessed for 6 replicates with substrate concentrations of 1 and 10 mM for both arginase 1 and arginase 2 ( Table 1) .
As the rate of arginase 1-mediated ORN formation from ARG was 20% higher in absence of manganese supplementation, manganese supplementation was not used in our experiments. Omission of manganese did not influence the shape of the rate-concentration curve (data not shown) and hence it was not expected to influence the kinetic parameters K m and K i .
The kinetic behaviour of the arginase 1 expression system was characterised at 0.05 mg/mL protein and 10-min incubation time. The kinetic parameters were derived from non-linear least squares fitting of experimental data for ARG conversion to ORN. For arginase 1, mean K m and V max values were 3.3 ± 0.2 mM and 34 ± 1 nmol·min −1 ·mg −1 , respectively. Characterisation of ARG conversion to ORN by arginase 2 was performed at SDMA were poor arginase 1 inhibitors at both ARG concentrations ( Table 3 ). An analogous trend emerged for arginase 2 inhibition by LYS and HOMOARG, while PRO, AG and methylated arginines were confirmed as poor inhibitors of each arginase isoenzymes. Experiments performed using arginase 2 and 2 mM ARG resulted in 18 and 94% inhibition by HOMOARG at the concentration of 1 and 10 mM, and 42 and 67% inhibition by LYS at 1 and 10 mM. At 100 µM ARG concentration, the conversion of ARG to ORN by arginase 2 was inhibited by 47 and 88% in the presence of 1 and 10 mM HOMOARG, and there was 44 and 88% inhibition by 1 and 10 mM LYS (Table 3 ). Similarly to arginase 1, no significant inhibition of arginase 2 was observed at physiological LYS and HOMOARG concentrations. The inhibitory potential was fully characterised for compounds showing 50% inhibition or more at the highest concentration used in these preliminary experiments, thus further characterisation was undertaken for LYS and HOMOARG only.
IC 50 and K i values determination for LYS and HOMOARG.
A full characterisation of the kinetic profile of arginase 1 and arginase 2 inhibition by LYS and HOMOARG was performed. The derived IC 50 and kinetic constants are reported in Table 4 . Experimental data for the inhibition of arginase 1 and 2 by LYS and HOMOARG were poorly fit by the equations for uncompetitive, noncompetitive and mixed inhibition. By contrast, data fitted well with the equation for the competitive model. Fitted values and statistical descriptors are given in Table 4 and fitted models, plotted with experimental data, are shown in Figs 5 and 6.
HOMOARG as a substrate for arginase 1 or arginase 2. The formation of LYS as a potential product of the reaction of HOMOARG with arginase 1 and arginase 2 was determined by UPLC-MS. Extracted ion chromatograms (EICs) were obtained with a mass window of 0.02 Da from total ion chromatograms (TIC) using m/z of 147.13 corresponding to the parent ion ([M + H] + ) for LYS. The retention time for LYS was 5.98 minutes as confirmed using pure LYS. LYS quantification was linear between 0 and 100 µM, with a limit of detection of 0.3 µM and a limit of quantitation of 1 µM (determined using a signal to noise ratio of 3:1 and 10:1, respectively) for the arginase 1 and arginase 2 assays. We could not detect the formation of LYS from HOMOARG in our experiments (data not shown).
Plasma homoarginine concentrations and arginine/ornithine ratio in humans.
The median age of the study population was 70 years (IQR 67-73). Mean baseline plasma concentrations of HOMOARG, ARG, and ORN were 2.36 ± 0.76 µmol/L, 305 ± 44 µmol/L, and 87 ± 16 µmol/L, respectively, whereas the mean ARG/ ORN ratio was 3.58 ± 0.69. After adjusting for age, sex, and estimated glomerular filtration rate, there were no significant correlations between plasma HOMOARG and ARG or ORN concentrations, and between HOMOARG concentrations and the ARG/ORN ratio. Similarly, there were no significant correlations between plasma LYS and the ARG/ORN ratio ( Table 5 ).
Discussion
Here we investigated the inhibitory potential of HOMOARG on arginase enzyme activity using a newly developed, robust, sensitive, and highly selective UPLC-MS assay that measured ORN formation from recombinant human arginase 1 and arginase 2. Additionally, we investigated the hypothesis that HOMOARG serves as a substrate of these enzymes. The effects of HOMOARG on arginase activity were compared to those of other endogenous compounds serving either as negative (PRO, AG, ADMA, SDMA and L-NMMA) or positive (LYS) controls. Furthermore, we assessed the associations between plasma concentrations of HOMOARG and the ARG/ORN ratio in a cohort of healthy older adults without significant disease states and/or pharmacological treatment that may affect the outcomes of interest. In our study, HOMOARG showed significant inhibitory effects towards arginase 1 and 2 activity at concentrations that are considerably higher than those reported clinically in plasma (2.01 ± 0.67 µM) or in the cytoplasm (2.37 ± 2.28 µM) of peripheral blood mononuclear cells 23 . Furthermore, there were no significant associations between plasma HOMOARG concentrations and the ARG/ORN ration in the human study.
Several studies have recently reported an inverse correlation between HOMOARG plasma concentrations and the risk of cardiovascular events and overall mortality [1] [2] [3] [4] [5] [6] [7] [8] . In some of these reports, arginase inhibition was proposed as a potential molecular mechanism accounting for the protective effect of HOMOARG in the 1, 7 . While our in vitro data confirm the inhibitory potential of HOMOARG on both arginase 1 and arginase 2, the lack of significant inhibition at physiological concentrations questions the biological and clinical significance of arginase inhibition as a key mechanism accounting for the observed cardio-protective effects of HOMOARG. To determine if HOMOARG was acting as a substrate for arginase 1 or arginase 2 we investigated the formation of LYS as the product from the reaction, instead of ORN 24 . Increasing concentrations of HOMOARG did not result in increasing concentrations of LYS. Therefore, we propose HOMOARG is not a substrate of arginase 1 or arginase 2 under our experimental conditions. Numerous studies have reported the kinetic characterisation of arginase 1 and arginase 2 activity [11] [12] [13] 15, 17, 25, 26 . By and large, published methods adopted colorimetric techniques for measuring urea formation in enzymatic reactions with ARG utilised as the substrate. Despite the advantages of this approach, such as low costs and high sensitivity, there are also significant limitations, in particular, poor specificity and reproducibility. By using mass spectrometry to detect and measure ORN as a product of arginase activity, our assay benefits from the inherent high selectivity and specificity of this technique. Another potential advantage of our approach is the use of un-purified protein in the form of EDTA-free lysates from HEK293T cells recombinantly expressing arginase 1 or arginase 2. This approach more closely mimics the in vivo environment by including the complexity of a cellular system. Furthermore, since our cellular lysates did not include chelating agents, and no purification steps were required to isolate the arginase 1 and arginase 2 proteins, manganese supplementation in kinetic experiments was not required. This allowed the use of phosphate buffer in the experimental system instead of "non-physiological" Tris-HCl. To demonstrate this point, we compared arginase activity in the presence and absence of manganese. Of particular note, we observed the rate of ORN formation was 20% higher in incubations undertaken in the absence of manganese, relative to samples in which 0.5 mM manganese chloride was supplemented to the incubation mixture. Despite the absence of manganese supplementation, the parameters derived from our experimental system were similar to those previously reported. For arginase 1 we determined the K m to be 3.3 ± 0.2 mM, which is within the range of 1-9 mM previously reported for arginase 1 [10] [11] [12] [13] 18, 27 . Similarly, for arginase 2 the K m value was 1.9 ± 0.1 mM, which is within the range of 1-7 mM previously reported 15, 17, 21, 27 .
The methylated arginines ADMA, SDMA and L-NMMA, chemical analogues of the substrate ARG and important modulators of the nitric oxide pathway, were confirmed as poor arginase inhibitors in agreement with a previous study 18 . Similarly, no significant inhibition was observed with PRO and AG. LYS reduced arginase 1 and arginase 2 activity by 37-42% and 67-78% at concentrations of 1 and 10 mM, respectively, when the inhibition experiments were conducted at the K m determined for ARG. A similar effect was observed at physiological ARG concentrations with 10 mM LYS inhibiting arginase 1 activity by 81% and arginase 2 activity by 88%. HOMOARG at concentrations of 1 and 10 mM was also effective in inhibiting arginase 1 and arginase 2 activity at concentrations of 0.1 and 2 mM (Table 3) .
A full kinetic characterisation of LYS and HOMOARG as arginase 1 and arginase 2 inhibitors was performed and, consistent with the report of Ikemoto et al. 12 , the K i values for arginase 1 inhibition by LYS and HOMOARG were found to be 1.8 and 6.1 mM, respectively (Ikemoto et al. reported K i = 2.5-2.7 mM for LYS and K i = 5.0-5.2 mM for HOMOARG). However, both LYS and HOMOARG exhibited a higher inhibitory potential on arginase 2 than previously reported, with IC 50 and K i values for LYS and HOMOARG of 0.9 and 0.5 mM (Colleluori et al. reported a K i = 7 mM) 15 and of 2.5 mM and 1.7 mM, respectively (Colleluori and Ash reported a K i of 39 mM) 17 .
Similar to HOMOARG, none of the experiments performed showed inhibition of the arginase isoenzymes when LYS was used at concentrations close to the reported circulating values (276 ± 120 µM) 22 .
It is important to emphasise that the results of enzymatic studies in isolation cannot easily translate into the complexity of a living system and account for other related and/or competing enzymatic pathways 28, 29 . However, when the experimental conditions are accurately chosen to match those present in vivo (particularly in terms of temperature, pH, buffer composition, and ionic strength), the findings can be used to speculate the physiological behaviour of the enzyme. Furthermore, good correlations are observed between in vitro kinetic experiments and in vivo K cat using approaches that combine computational flux predictions and proteomics data 30 .
Using a cohort of healthy older adults, we further tested the hypothesis that plasma HOMOARG concentrations may be positively associated with the ARG/ORN ratio, a proposed indicator of arginase activity 31 . The lack of a significant correlation between HOMOARG concentrations and the ARG/ORN ratio in our study is in contrast to a previous study by Marz et al. that reported a significant positive correlation (r = 0.32; P = < 0.001) in 3,305 subjects with high cardiovascular risk 1 . There are several significant differences between the two studies: 1) the ARG/ORN ratio in our study (3.58 ± 0.69) is significantly higher than the ratio reported by Marz et al.
(1.47 ± 0.42); (2) The study by Marz et al. included patients with diabetes and hypertension. Interestingly, both these conditions are associated, per se, with an increase in arginase activity; 32, 33 and perhaps most importantly, (3) our cohort includes only healthy subjects, while the LURIC cohort comprised individuals with different pathological conditions, extremes of renal function and subjects undertaking different medications, all conditions that affect arginase activity 34 .
Although arginase inhibition is unlikely to be a key mechanism involved in the putative cardioprotective effects of HOMOARG, other mechanisms may play a role. For example HOMOARG is reported to be an alternative substrate for the enzyme NOS 20, 35 , and despite its low affinity for the enzyme, it can directly increase NO availability 1 . Likewise, HOMOARG is a substrate of the different members of the cationic amino acid transporter (CAT) family of transporters and significantly inhibits the uptake of ARG by CAT-1, thus increasing ARG availability for NOS 36 . Furthermore, it may reduce blood pressure by facilitating the excretion of nitrate 1, 37 .
In conclusion, HOMOARG-mediated arginase 1 and arginase 2 inhibition was observed at concentrations that are significantly higher than those observed in plasma or serum and in the cytoplasm. In support of this observation, there was no association between plasma HOMOARG and the ARG/ORN ratio in a cohort of healthy older adults. As such, arginase inhibition is unlikely to play a significant role in the protective effects of HOMOARG against cardiovascular risk and mortality. Arg/Orn r = 0.05 P = 0.73 r = 0.02 P = 0.92 r = 0.41 P = 0.006 r = −0.63 P < 0.001 - Table 5 . Partial correlations, adjusted for age, sex, and estimated glomerular filtration rate, between plasma homoarginine, lysine, arginine, and ornithine concentrations, and the arginine/ornithine ratio (Arg/Orn) * . 
Methods
In vitro studies. The experimental protocols for the assessment of arginase 1 and 2 inhibition in vitro, described below, were approved by the Institutional Biosafety Committee of Flinders University (IBC No 2009-08). All methods were performed in accordance with the relevant guidelines and regulations.
Data availability. The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Materials
Deuterated L-ornithine (ORN-d6), NG, N′G-dimethyl-L-arginine dihydrochloride (SDMA), and L-NGmonomethyl arginine (L-NMMA) acetate were obtained from Sapphire Bioscience (Sapphire Bioscience, Redfern, Australia). High purity water was obtained using a MilliQ Synergy UV Ultrapure water system (Merck Millipore, Sydney, Australia). Acetonitrile (LC-MS Grade), 2-propanol and formic acid (HPLC Grade) were obtained from Merck Millipore (Merck Millipore, Melbourne, Australia). All other laboratory grade chemicals and reagents were purchased from Sigma-Aldrich (Sigma-Aldrich, Sydney, Australia). Stock solutions of 1 M ARG, 100 mM ORN, LYS, PRO, AG, HOMOARG and 10 mM L-NMMA, SDMA and ADMA, together with a 1 mg/mL stock solution of ORN-d6 were prepared in purified water. These solutions were stored frozen at −20 °C. The working internal standard solutions were prepared by diluting the 1 mg/mL ORN-d6 stock solution with water to 300 µM or 1200 µM final concentration. These working internal standard solutions were stored frozen at −20 °C. Arginase 1 and arginase 2 cloning and expression. The C-terminal cMYC-FLAG-tagged human arginase 1 (NM_000045) and arginase 2 (NM_001172) coding sequences (CDS) were purchased from Origene (OriGene Technologies, Rockville, MD) and shuttled into the pEF-IRES(6) mammalian expression vector. Cells were transfected with the pEF-IRES-arginase 1 or with the pEF-IRES-arginase 2 expression constructs (4 μg) using Lipofectamine2000 in OptiMEM (Invitrogen, CA, USA). The stable expression of arginase 1 and arginase 2 was achieved in HEK293T cells using puromycin as the selectable antibiotic.
A single batch of recombinant arginase 1 and arginase 2 was used in all experiments to avoid batch-related variability. Cultured cells were grown to 90% confluence, harvested, washed in phosphate-buffered saline solution and lysed by sonication in phosphate buffer (0.1 M, pH = 7.4) supplemented with an EDTA-free complete protease inhibitor cocktail (Roche Diagnostic GmbH, Mannheim, Germany) and 1 mM PMSF. Cell lysates were centrifuged for 10 minutes at 4 °C at 18000 xg to remove cellular debris and the supernatant fractions aliquoted to avoid repeated freeze thaw cycles and subsequently stored at −80 °C until use. Protein concentrations were determined by the method of Lowry 38 .
Western blot analysis. Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was performed on cell lysates using 10% acrylamide gels to separate the denatured protein (120 V), and then transferred to Trans-Blot ® Transfer Medium pure nitrocellulose (BIORAD; 0.45 μm; 100 V). Membranes were blocked in 4% (w/v) non-fat milk in Tris-buffered saline Tween20 for 90 mins with the primary immunodetection of arginase 1 and arginase 2 proteins achieved by probing blots with anti-arginase 1 (Santa Cruz, CA; 1:1000), anti-arginase 2 (Santa Cruz, CA; 1:1000,), and anti-FLAG (Sigma-Aldrich, Sydney, Australia; 1:5000) antibodies. Subsequently, blots were incubated with the corresponding peroxidase conjugated secondary antibodies (1:2000, 1 hour), with immunoreactivity detected using the SuperSignalWest Pico Chemiluminescent (ECL) HRP substrate (Thermo Fisher Scientific, Victoria, Australia) and imaged using the ImageQuant LAS-400 image reader (Fujifilm, Japan).
Analytical instrumentation. ORN, LYS and ARG separation, detection and quantification were performed on a Waters ACQUITY TM Ultra Performance LC ™ system coupled to a Waters Premier quadrapole time of flight (qToF) mass spectrometer (Waters, Sydney, Australia). The electrospray ionisation (ESI) source was operated in positive ionisation mode (V+) and data collected over 10 min in ToF MS mode between 50 and 1000 Da with an instrument scan time of 1 sec and inter-scan delay of 0.1 sec. The mass spectrometer parameters are shown in Table 6 . Instrument control, data acquisition and data processing were performed using Waters MassLynx software (version 4.1, Waters, Sydney, Australia).
UPLC-MS analysis of ORN. ORN was separated from the cellular lysate components on a Waters Atlantis TM
HILIC column (2.1 × 150 mm, 3 µm, Waters, Sydney, Australia) held at 35 °C. The mobile phase comprised acetonitrile containing 0.1% v/v formic acid (mobile phase A) and 0.1% formic acid in a solution of 10% v/v acetonitrile in water (mobile phase B) at a flow rate of 0.4 mL/min. Initial conditions were 70% mobile phase A, 30% mobile phase B. The proportion of mobile phase B was increased linearly to 45% over 7.4 min, held at 45% for 1 min then returned to 30% for 1.6 min to re-establish equilibrium prior to injection of the following sample.
The method was assessed for linearity, reproducibility and sensitivity (limit of detection and limit of quantitation). Limit of quantitation was determined as the concentration of product giving 10:1 signal to noise ratio, while the limit of detection was assigned as the concentration corresponding to 3:1 signal to noise ratio. Calibration standards comprised of ORN concentrations ranging from 0 to 200 µM spiked into the incubation mixture and were extracted and reconstituted following the same procedure used for incubation samples.
Arginase activity assay. ORN Following a 5-min pre-equilibration period reactions were initiated by the addition of the cell lysate solution in 0.05 M phosphate buffer to a pre-equilibrated aqueous solution of the substrate (ARG). Following incubation at 37 °C the reaction was terminated by the addition of 300 μL 0.1% formic acid in 2-propanol and 10 µL of the assay internal standard ORN-d6 was added to each reaction tube. For the arginase 1 assay the incubation time was 10 min and the assay working internal standard solution was 1200 μM ORN-d6. For arginase 2 assays the incubation time was 20 min and the ORN-d6 working internal standard concentration was 300 μM
The samples were vortex mixed (20 sec) and cooled in an ice/water bath for 10 min prior to centrifugation (5 min, 18,000 × g, room temperature) to precipitate the proteins. An aliquot of the supernatant layer was diluted with a 7:3 mobile phase A/mobile phase B solution into glass UPLC vial inserts. For UPLC-MS analysis the arginase 1 sample supernatant layer was diluted 1:20 with the mobile phase solution and 2 μL of each diluted sample was injected for ORN analysis whereas arginase 2 analysis was performed by diluting the supernatant layer 1:10 and injecting 5 μL for analysis.
To determine if manganese supplementation was necessary, we performed an experiment using arginase 1 (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), ARG (0 to 10 mM) and manganese chloride (0 or 0.5 mM). Incubation samples were incubated for 20 min and protein was precipitated and samples prepared for ORN analysis as previously described.
Samples were maintained at 15 °C in the auto-sampler prior to analysis.
Arginase inhibition. Incubation mixtures comprised of HEK293T cell lysate expressing arginase 1 (0.05 mg/ mL) or arginase 2 (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), inhibitor (0, 0.1, 1, 10, 100, 1000 or 10000 μM) and ARG (0.1, 2 or 3 mM). Following a 5-min pre-incubation of the potential inhibitor with arginase 1 or arginase 2, reactions were initiated by the addition of a pre-equilibrated solution of the substrate ARG. Protein precipitation and preparation for ORN analysis was performed as described above (see arginase activity assay).
IC 50 experiments. For arginase 1 assay incubation mixtures comprised of arginase 1 cell lysate (0.05 mg/ mL), phosphate buffer (0.05 M, pH 7.4), LYS or HOMOARG (0-10 mM) and ARG (3 mM). Incubation, protein precipitation and preparation for ORN analysis were performed as previously described (see arginase inhibition and arginase activity assay). For arginase 2 assay incubation mixtures comprised of arginase 2 cell lysate (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), LYS (0-2.5 mM) or HOMOARG (0-5 mM) and ARG (2 mM). Incubation, protein precipitation and preparation for ORN analysis were performed as described above (see arginase inhibition and arginase activity assay).
K i experiments.
For arginase 1 incubation mixtures comprised of arginase 1 cell lysate (0.05 mg/mL), phosphate buffer (0.05 M, pH 7.4), LYS or HOMOARG (0-10 mM) and ARG (0.6-15 mM). Incubation, protein precipitation and preparation for ORN analysis were performed as previously described (see arginase inhibition and arginase activity assay).
For arginase 2 incubation mixtures comprised of arginase 2 lysate (0.1 mg/mL), phosphate buffer (0.05 M, pH 7.4), LYS (0-2 mM) or HOMOARG (0-4 mM) and ARG (0.5-8 mM). Incubation, protein precipitation and preparation for ORN analysis was performed as described above (see arginase inhibition and arginase activity assay). Sample were diluted 3:17 in mobile phase solution prior injection.
In vivo studies
Homoarginine, lysine and arginine/ornithine ratio in humans. Plasma concentrations of HOMOARG, LYS, ARG, and ORN were measured, using an Aquity UPLC (Waters, Sydney, Australia) coupled to a qToF Premier high-resolution mass spectrometer (Waters, Sydney, Australia), in 50 healthy community dwelling adults > 65 years (27 males and 23 females) participating in a study investigating the effects of fish oil consumption on adaptations to resistance exercise 39 . Study participants had no previous history of significant disease and were not on regular medications, barring one female participant treated with angiotensin converting enzyme IC 50 values for arginase 1 and arginase 2 inhibition by LYS and HOMOARG were determined by fitting the IC 50 equation to experimental data using the same software and data are the mean of two singlicate experiments.
Fitting of the experimental data to noncompetitive, mixed and uncompetitive inhibition models was performed using EnzFitter and comparison of the statistical values was used to determine the best fit. K i values were derived from fitting the competitive inhibition equation to experimental data. K i data are the mean of three singlicate experiments.
Goodness of fit of all equations was assessed from the F statistic, 95% confidence intervals, r 2 value, and standard error of the parameter fit.
Associations between HOMOARG, ARG, and ORN concentrations, and ARG/ORN ratios in the human study were assessed by partial correlations, adjusted for age, sex, and estimated glomerular filtration rate. Analyses were performed using IBM SPSS Statistics Version 23, Release 23.0.0.2 (SPSS Inc., Armonk, NY, USA). A two-sided P < 0.05 indicated statistical significance.
